Fusion Antibodies (FAB) Competitors GBX 6.90 +0.05 (+0.73%) As of 12:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock FAB vs. SAR, AOR, OPTI, AREC, IMM, POLB, RLM, NSCI, SNG, and IXIShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Arecor Therapeutics (AREC), ImmuPharma (IMM), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), Synairgen (SNG), and IXICO (IXI). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. Sareum AorTech International OptiBiotix Health Arecor Therapeutics ImmuPharma Poolbeg Pharma Realm Therapeutics NetScientific Synairgen IXICO Fusion Antibodies (LON:FAB) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings. Does the MarketBeat Community believe in FAB or SAR? Sareum received 28 more outperform votes than Fusion Antibodies when rated by MarketBeat users. However, 68.35% of users gave Fusion Antibodies an outperform vote while only 66.13% of users gave Sareum an outperform vote. CompanyUnderperformOutperformFusion AntibodiesOutperform Votes5468.35% Underperform Votes2531.65% SareumOutperform Votes8266.13% Underperform Votes4233.87% Which has stronger earnings and valuation, FAB or SAR? Fusion Antibodies has higher revenue and earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFusion Antibodies£2.09M3.10-£4.10M-£4.45-1.55SareumN/AN/A-£5.28M-£4.22-3.55 Is FAB or SAR more profitable? Sareum has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat Sareum's return on equity.Company Net Margins Return on Equity Return on Assets Fusion Antibodies-195.95% -137.11% -63.78% Sareum N/A -270.25%-113.80% Do institutionals and insiders have more ownership in FAB or SAR? 21.0% of Fusion Antibodies shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by company insiders. Comparatively, 5.0% of Sareum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, FAB or SAR? Fusion Antibodies has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, suggesting that its stock price is 208% less volatile than the S&P 500. Does the media refer more to FAB or SAR? In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Sareum'saverage media sentiment score. Company Overall Sentiment Fusion Antibodies Neutral Sareum Neutral SummaryFusion Antibodies beats Sareum on 9 of the 12 factors compared between the two stocks. Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.49M£128.97M£5.33B£2.62BDividend YieldN/A3.74%5.20%5.05%P/E Ratio-1.553.4226.72134.60Price / Sales3.104,168.72395.56221,328.11Price / Cash9.0213.1938.3228.03Price / Book1.9633.216.763.84Net Income-£4.10M-£91.56M£3.23B£5.88B7 Day Performance2.99%3.50%0.41%3.54%1 Month PerformanceN/A7.75%9.12%25.38%1 Year Performance89.04%102.80%18.74%130.62% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 6.90+0.7%N/A+91.0%£6.49M£2.09M-1.5548Gap UpSARSareumN/AGBX 16.25-9.7%N/A-52.6%£20.30MN/A-3.853,211Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539,000.00-33.383OPTIOptiBiotix HealthN/AGBX 19+5.6%N/A-2.5%£18.61M£590,009.23-6.011News CoverageARECArecor TherapeuticsN/AGBX 41.18+0.4%N/A-72.6%£15.55M£6.04M-1.4610News CoverageInsider TradeGap UpIMMImmuPharmaN/AGBX 3.53+4.6%N/A+19.3%£14.99M£-71,310.29-6.0913Earnings ReportPOLBPoolbeg PharmaN/AGBX 2.90+1.8%N/A-80.5%£14.91MN/A0.0012News CoverageEarnings ReportGap DownRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626SNGSynairgenN/AN/AN/AN/A£9.04MN/A-0.5634Gap DownIXIIXICON/AGBX 9.03-2.4%N/A+55.2%£8.36M£11.50M-2.3489Earnings ReportGap Down Related Companies and Tools Related Companies Sareum Alternatives AorTech International Alternatives OptiBiotix Health Alternatives Arecor Therapeutics Alternatives ImmuPharma Alternatives Poolbeg Pharma Alternatives Realm Therapeutics Alternatives NetScientific Alternatives Synairgen Alternatives IXICO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FAB) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.